Immunome News - IMNM

Company Name	Stock Ticker Symbol	Market	Type
Immunome Inc	IMNM	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	0.29	2.03%	14.55	07:27:14

Open Price	Low Price	High Price	Close Price	Prev Close
				14.26

more quote information »

Recent News

Date	Time	Source	Heading
4/25/2024	8:52	IHNW	FeaturedCannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA
4/25/2024	08:26	BW	Immunome Appoints Sandra M. Swain to Board of Directors
4/05/2024	08:00	BW	Immunome to Present Preclinical Data for IM-3050, Its Lead..
3/28/2024	16:02	BW	Immunome Reports Full Year 2023 Financial Results and..
3/26/2024	08:00	BW	Immunome Completes Acquisition of AL102, a Phase 3 Asset for..
3/07/2024	08:00	BW	Immunome to Participate in the Leerink Partners Global..
3/01/2024	08:00	BW	Immunome to Participate in the TD Cowen 44th Annual..
2/21/2024	21:10	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2/21/2024	21:07	EDGAR2	Form 3 - Initial statement of beneficial ownership of..
2/20/2024	08:15	BW	Immunome Recognizes Ayala Pharmaceuticals’ Announced..
2/16/2024	16:05	BW	Immunome Announces Closing of Public Offering and Full..
2/14/2024	16:11	EDGAR2	Form 8-K - Current report
2/14/2024	16:09	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
2/13/2024	22:38	BW	Immunome Announces Pricing of Public Offering of Common..
2/13/2024	16:36	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
2/13/2024	16:10	EDGAR2	Form 8-K - Current report
2/13/2024	16:05	BW	Immunome Announces Proposed Public Offering of Common Stock
2/12/2024	14:10	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
2/06/2024	08:05	EDGAR2	Form 8-K - Current report
2/05/2024	08:00	BW	Immunome to Present at the Guggenheim Healthcare Talks 6th..
2/02/2024	16:04	EDGAR2	Form S-8 - Securities to be offered to employees in employee..
1/31/2024	20:53	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
1/31/2024	20:50	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
1/11/2024	17:27	EDGAR2	Form 8-K - Current report
1/08/2024	07:05	EDGAR2	Form 8-K - Current report
1/08/2024	07:00	BW	Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug..
1/04/2024	17:40	EDGAR2	Form 3 - Initial statement of beneficial ownership of..
1/04/2024	08:00	BW	Immunome Appoints Phil Roberts as Chief Technical Officer
1/03/2024	08:00	BW	Immunome to Present at the 42nd Annual J.P. Morgan..
1/02/2024	08:05	EDGAR2	Form 8-K - Current report
1/02/2024	08:00	BW	Immunome Appoints Carol A. Schafer to Board of Directors
12/29/2023	17:00	EDGAR2	Form 8-K - Current report
12/26/2023	08:35	EDGAR2	Form 8-K - Current report
12/26/2023	08:30	BW	Immunome to Acquire Antibody-Related Assets and Materials..
12/15/2023	19:28	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/05/2023	21:08	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/28/2023	00:15	EDGAR2	Form EFFECT - Notice of Effectiveness
11/22/2023	16:02	EDGAR2	Form 8-K/A - Current report: [Amend]
11/16/2023	16:08	EDGAR2	Form S-3 - Registration statement under Securities Act of..
11/15/2023	06:03	EDGAR2	Form 8-K - Current report
11/10/2023	08:00	BW	Immunome to Present at the Stifel 2023 Healthcare Conference
11/09/2023	16:52	EDGAR2	Form 8-K - Current report
11/09/2023	08:00	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/09/2023	08:00	BW	Immunome Reports Third Quarter 2023 Financial Results
11/08/2023	08:30	EDGAR2	Form 8-K - Current report
11/08/2023	08:00	BW	Immunome Appoints Jean-Jacques Bienaimé to Board of..
10/31/2023	18:35	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/31/2023	18:32	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/31/2023	18:30	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/19/2023	08:00	BW	Immunome Appoints Bob Lechleider, M.D., as Chief Medical..
10/12/2023	16:39	EDGAR2	Form SC 13D - General statement of acquisition of beneficial..